InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,127.79
(
1.26%
)
US TECH 100
17,446.00
(
2.17%
)
Dow Jones
38,675.68
(
1.18%
)
Brent Oil
82.77
(
0.00%
)
Bitcoin
64,020.64
(
0.21%
)
Post# of 3647
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

RXEXEC

Send PM Follow Ignore
Followers 0
Posts 4
Boards Moderated 0
Alias Born 04/20/2021

RXEXEC

Re: None

Monday, 11/15/2021 1:13:07 PM

Monday, November 15, 2021 1:13:07 PM

Post# of 3647
Not exactly direct competition with Venturis/CVBT's FGF-1 but Phase 2 data published on angiogenesis with VEGF-A from AZ and Moderna produced in vivo using mRNA injected directly into the heart.

The therapy, AZD8601, encodes for vascular endothelial growth factor (VEGF-A), a protein that induces the growth of blood vessels, and in a phase 2a trial met its primary endpoints of safety and tolerability in patients with heart failure.

https://www.fiercebiotech.com/biotech/aha-astrazeneca-moderna-shine-early-light-mrna-potential-heart-failure?oly_enc_id=6899J3333067F8K
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up